The 2012 Japan Prize

• Field:
  Healthcare and Medical Technology
• Achievement:
  Development of a new therapeutic drug targeting cancer-specific molecules
• Lecture:
  Successful Approach Targeting Leukemic Cells

Major Honors

2001	AACR-Richard and Hinda Rosenthal Foundation Award
2001	Warren Alpert Foundation Prize, Harvard Medical School
2001	Dameshek Prize, The American Society of Hematology
2002	Medal of Honor, American Cancer Society
2002	Charles F. Kettering Prize, General Motors Cancer Research Foundation
2003	David A. Karnofsky Award, American Society of Clinical Oncology
2007	Keio Medical Science Prize
2009	The Lasker-DeBakey Clinical Medical Research Award, with Lydon and Sawyers
2009	Meyenburg Cancer Research Prize
2011	Ernest Beutler Lecture and Prize by American Society of Hematology

Membership

2003	Member, the Institute of Medicine of National Academies
2006	Member, the American Association of Physician
2007	Member, the National Academy of Science

Academic Degrees

1981	M.D. from the University of California, San Diego

Professional Career

1981-1984	Internship & residency at Barnes Hospital, Washington University School of Medicine, St. Louis
1984	American Board of Internal Medicine
1984-1987	Fellow, Dana-Farber Cancer Institute, Harvard Medical School
1987	American Board of Internal Medicine, Medical Oncology
2002	Howard Hughes Medical Institute
2007	Professor and Director of OHSU Knight Cancer Institute, Oregon Health & Science University

Major Publications

• Druker, B.J., Mamon, H.J. & Roberts, T.M. Oncogenes, growth factors, and signal transduction. N. Engl. J. Med. 321, 1383–1391, 1989
• Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., & Lydon, N.B.. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566, 1996
• Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, JM, Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031–1037, 2001.
• Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539, 2002.
• Druker B.J., Guilhot F., O'Brien S.G. et al. Five-year follow-up of patients receiving matinib for chronic myeloid leukemia". N. Engl. J. Med. 355: 2408–2417, 2006.